An online discrete choice experiment elicited preferences for longer-acting preexposure prophylaxis (LA-PrEP) product and delivery characteristics among 90 transgender women in the United States. Over 10 questions, respondents chose between two hypothetical LA-PrEP options defined by product type, side effects, clinic type, appointment duration, and cost; or neither option (their current HIV prevention method). An LA-PrEP method was chosen over the current HIV prevention option in 94% of questions. Only cost significantly influenced LA-PrEP choice.
Roberts et al. (Thu,) studied this question.